FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280920> ?p ?o ?g. }

• W4379280920 endingPage "7523" @default.
• W4379280920 startingPage "7523" @default.
• W4379280920 abstract "7523 Background: the POLARIX study, pts with previously untreated DLBCL were randomized to Pola-R-CHP or R-CHOP (NCT03274492; Tilly et al. 2022). We previously validated the prognostic value of ctDNA at baseline and after one cycle of therapy in POLARIX (Herrera et al. 2022); here, we evaluate the relationship between ctDNA clearance and PFS and OS. Methods: Pts were included if baseline and longitudinal ctDNA results were available. Plasma ctDNA was measured at baseline, Cycle (C) 5 Day (D) 1, and end of treatment (EOT), with the AVENIO NHL CAPP-Seq assay (Stokowski et al. 2022). ctDNA clearance was determined as previously described (Herrera et al. 2022). PFS and OS according to ctDNA status were reported as landmarked hazard ratios (HR) and 3-yr rates. HRs were adjusted for IPI score (>2), region, bulky disease (>7.5cm), age (>60 years), and cell of origin. Results: At baseline, 654 pts had ctDNA results; 494 (76%) and 519 (79%) pts were evaluable at C5D1 and EOT, respectively. Undetectable ctDNA (ctDNA−) was achieved by 57% (152/265) of Pola-R-CHP-treated pts and 59% (135/229) of R-CHOP-treated pts at C5D1 (p=0.79), and by 66% (172/262) of Pola-R-CHP-treated pts and 67% (172/257) of R-CHOP-treated pts at EOT (p=0.83). Achieving ctDNA− was prognostic for PFS and OS in each treatment arm at C5D1 and EOT (Table). Pts in the Pola-R-CHP arm who had complete response (CR) with PET-CT and ctDNA− at EOT had superior PFS and OS compared with pts with CR and detectable ctDNA (ctDNA+) at EOT (PFS HR 0.30, 95% confidence interval [CI]: 0.14–0.66; OS HR 0.20, 95% CI: 0.07–0.60). This was not observed with R-CHOP (PFS HR 0.74, 95% CI: 0.34–1.63; OS HR 1.11, 95% CI: 0.30–4.16). Among pts with CR and ctDNA− at EOT, pts treated with Pola-R-CHP had superior PFS vs R-CHOP (HR 0.41, 95% CI: 0.21–0.82); this was not observed with OS (HR 0.41, 95% CI: 0.14–1.18). There was no statistically significant difference in PFS between treatment arms in pts with CR and ctDNA+ at EOT (PFS HR 1.20, 95% CI: 0.49–2.83). Conclusions: Achieving ctDNA− at C5D1 and EOT was prognostic for longer survival. Although no difference was observed in the number of pts with ctDNA− at EOT between arms, pts achieving CR and ctDNA− at EOT had superior PFS in the Pola-R-CHP vs the R-CHOP arm, suggesting deeper molecular responses in pts treated with Pola-R-CHP beyond the detection sensitivity of the assay used in this analysis. Clinical trial information: NCT03274492 . [Table: see text]" @default.
• W4379280920 created "2023-06-05" @default.
• W4379280920 creator A5003078312 @default.
• W4379280920 creator A5013007045 @default.
• W4379280920 creator A5019218337 @default.
• W4379280920 creator A5026641386 @default.
• W4379280920 creator A5030788778 @default.
• W4379280920 creator A5038526399 @default.
• W4379280920 creator A5039142430 @default.
• W4379280920 creator A5051605599 @default.
• W4379280920 creator A5061466414 @default.
• W4379280920 creator A5071395496 @default.
• W4379280920 creator A5077150302 @default.
• W4379280920 creator A5077244480 @default.
• W4379280920 creator A5082700087 @default.
• W4379280920 creator A5082892912 @default.
• W4379280920 creator A5086354986 @default.
• W4379280920 creator A5090860833 @default.
• W4379280920 creator A5091800861 @default.
• W4379280920 date "2023-06-01" @default.
• W4379280920 modified "2023-10-14" @default.
• W4379280920 title "Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study." @default.
• W4379280920 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7523" @default.
• W4379280920 hasPublicationYear "2023" @default.
• W4379280920 type Work @default.
• W4379280920 citedByCount "0" @default.
• W4379280920 crossrefType "journal-article" @default.
• W4379280920 hasAuthorship W4379280920A5003078312 @default.
• W4379280920 hasAuthorship W4379280920A5013007045 @default.
• W4379280920 hasAuthorship W4379280920A5019218337 @default.
• W4379280920 hasAuthorship W4379280920A5026641386 @default.
• W4379280920 hasAuthorship W4379280920A5030788778 @default.
• W4379280920 hasAuthorship W4379280920A5038526399 @default.
• W4379280920 hasAuthorship W4379280920A5039142430 @default.
• W4379280920 hasAuthorship W4379280920A5051605599 @default.
• W4379280920 hasAuthorship W4379280920A5061466414 @default.
• W4379280920 hasAuthorship W4379280920A5071395496 @default.
• W4379280920 hasAuthorship W4379280920A5077150302 @default.
• W4379280920 hasAuthorship W4379280920A5077244480 @default.
• W4379280920 hasAuthorship W4379280920A5082700087 @default.
• W4379280920 hasAuthorship W4379280920A5082892912 @default.
• W4379280920 hasAuthorship W4379280920A5086354986 @default.
• W4379280920 hasAuthorship W4379280920A5090860833 @default.
• W4379280920 hasAuthorship W4379280920A5091800861 @default.
• W4379280920 hasConcept C126322002 @default.
• W4379280920 hasConcept C143998085 @default.
• W4379280920 hasConcept C207103383 @default.
• W4379280920 hasConcept C2778559949 @default.
• W4379280920 hasConcept C2779338263 @default.
• W4379280920 hasConcept C2989005 @default.
• W4379280920 hasConcept C44249647 @default.
• W4379280920 hasConcept C71924100 @default.
• W4379280920 hasConcept C90924648 @default.
• W4379280920 hasConceptScore W4379280920C126322002 @default.
• W4379280920 hasConceptScore W4379280920C143998085 @default.
• W4379280920 hasConceptScore W4379280920C207103383 @default.
• W4379280920 hasConceptScore W4379280920C2778559949 @default.
• W4379280920 hasConceptScore W4379280920C2779338263 @default.
• W4379280920 hasConceptScore W4379280920C2989005 @default.
• W4379280920 hasConceptScore W4379280920C44249647 @default.
• W4379280920 hasConceptScore W4379280920C71924100 @default.
• W4379280920 hasConceptScore W4379280920C90924648 @default.
• W4379280920 hasIssue "16_suppl" @default.
• W4379280920 hasLocation W43792809201 @default.
• W4379280920 hasOpenAccess W4379280920 @default.
• W4379280920 hasPrimaryLocation W43792809201 @default.
• W4379280920 hasRelatedWork W2012238656 @default.
• W4379280920 hasRelatedWork W2021276212 @default.
• W4379280920 hasRelatedWork W2117629472 @default.
• W4379280920 hasRelatedWork W2119954546 @default.
• W4379280920 hasRelatedWork W2572837865 @default.
• W4379280920 hasRelatedWork W2806991430 @default.
• W4379280920 hasRelatedWork W3000225679 @default.
• W4379280920 hasRelatedWork W4239668963 @default.
• W4379280920 hasRelatedWork W4250870498 @default.
• W4379280920 hasRelatedWork W4308147535 @default.
• W4379280920 hasVolume "41" @default.
• W4379280920 isParatext "false" @default.
• W4379280920 isRetracted "false" @default.
• W4379280920 workType "article" @default.